

MADRIGAL ABSTRACT

○ **Investment Rational**

Madrigal develops an innovative delivery system based on nano-capsulated psychoactive compounds. Psychoactive market (psytech) undergoes a renaissance and is considered as a promising area in treatment of various mental disorders. Our first candidate is an intranasal psilocybin for treatment of PTSD, which is in an advanced R&D stage. The company's interdisciplinary management team include experienced entrepreneurs, businessmen, and top scientists.

○ **Business Strategy**

The company has proven technological capabilities for containing various nano-encapsulated molecules. At first, we are developing a direct nose-to-brain delivery system for accurate & efficient dosing treatment of mental health. We aimed at collaborating with a pharmaceutical company that will take our delivery system into the market.

○ **Core Technology**

The company's core technology is nano-encapsulation of psychoactive compounds. Our uniqueness is the innovative formation of the nanoparticles, which is based on common compounds assembled by covalent bonds, providing higher stability and accuracy. Our nano-encapsulation system, together with our partners in the academia, enable us to encapsulate almost any molecule and screen a range of mental disorders.

○ **Product Profile/Pipeline**

Most psytech companies deal with active substance and treatment methodologies, only few develop delivery systems. Madrigal aims at providing a game-changer delivery system. Beside our partners in the academia, we have collaborated with researchers in the field of mushroom genetics. Potential collaborations are psytech companies that are looking for technologies and pharma companies seeking to get involved in psytech industry.

○ **What's Next?**

Each R&D cycle begins with purification, encapsulation, and screening for *in-vitro* activity of candidate molecules inhouse. The best candidates introduce into pre-clinical trials outsource. Our first candidate is in an advanced R&D phase and prior to the preclinical trials, others at first R&D stages. The company plans to hire more R&D employees and looking for fundings to begin preclinical trials.